Efgartigimod for generalized myasthenia gravis in the extreme elderly (≥80 years): a multicenter retrospective real-world study
This multicenter study demonstrated that efgartigimod was efficacious and safe in the elderly MG over 80 years of age. Elderly patients with MGAE presented to benefit the most from efgartigimod treatment.
Authors
- Chao Yuan (ORCID: https://orcid.org/0000-0001-6044-2925)
- Rong Yang (ORCID: https://orcid.org/0000-0002-0193-6949)
- Zhenhua Yuan (ORCID: https://orcid.org/0000-0001-8505-6000)
- Ping-Ping Kong
- Teng Jiang (ORCID: https://orcid.org/0000-0003-4170-1156)
- Jian‐Quan Shi (ORCID: https://orcid.org/0000-0003-0536-1131)
- Hong-Dong Zhao
- Jing Chen (ORCID: https://orcid.org/0000-0002-0024-4561)
- Shiqi Huang
- Jie Lu
- Hong Ye
Institutions
- Nanjing University of Chinese Medicine (CN)
- Soochow University (CN)
- Nanjing Brain Hospital (CN)
- Second Affiliated Hospital of Soochow University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-06
- DOI
- https://doi.org/10.3389/fimmu.2025.1685233
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00